Tests hesperidin supplement for fatigue and mood in multiple sclerosis
Tests a daily citrus-derived supplement against placebo in adults with multiple sclerosis.
Key facts
- Who runs it
- Swansea University
- Where
- Swansea, United KingdomSee the site
- Trial code
- Registry title
- Hesperidin RCT in MS
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 7 Jan 2026
- Expected to end
- 18 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hesperidin
- Placebo
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis. It tests whether hesperidin supplement or a placebo for 12 weeks helps fatigue, mood and thinking.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of multiple sclerosis. No stage or severity is stated.
Main reasons for not taking part
- Known food allergies or intolerances
- Significant stomach or gut (gastrointestinal) problems
- Under 18 years of age
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosis of Multiple Sclerosis, Aged 18 years or older
Who cannot take part
- Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years
Where in United Kingdom
- FHMLS, Nutrition LabSwansea, United KingdomContact: Hayley A Young, PHDTaking people
About the trial
What the trial wants to find out
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.
Read full original descriptionShow less
Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
The 2 groups in the trial
- HesperidinExisting treatment, for comparison
Participants receiving Hesperidin capsules for 12 weeks.
- Placebo ComparatorPlacebo, for comparison
Participants receiving matching placebo capsules for 12 weeks.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
- Plain-language title
- Tests hesperidin supplement for fatigue and mood in multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 March 2026